{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:37:09Z","timestamp":1770154629650,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background: Canine splenic hemangiosarcoma (HSA) is a fatal malignancy, and most affected dogs die within a few months of diagnosis. Most dogs present with signs from tumor rupture, resulting in hemoabdomen and intra-abdominal dissemination. The abdomen is also the main site of disease recurrence.<\/jats:p>\n                  <jats:p>Hypothesis: Intraperitoneal (IP) administration of doxorubicin will delay or prevent intra-abdominal tumor recurrence and prolong survival in dogs with HSA.<\/jats:p>\n                  <jats:p>Animals: Fourteen dogs with splenic HSA.<\/jats:p>\n                  <jats:p>Methods: A prospective, unmasked, uncontrolled clinical trial. After staging of disease status and splenectomy, pegylated liposomal encapsulated doxorubicin was administered intraperitoneally (1 mg\/kg body weight) every 3 weeks for 4 cycles. All dogs were monitored for recurrence of HSA. Samples of plasma and abdominal fluid were collected for measurement of doxorubicin concentration and pharmacokinetic analysis. Nonlinear mixed-effect modeling was used to describe the pharmacokinetics of liposomal doxorubicin administered IP.<\/jats:p>\n                  <jats:p>Results: All 14 dogs died, 12 because of HSA and 2 from other causes. Postmortem examination was performed on 12 dogs. All 12 dogs died because of HSA-related causes and had hepatic metastases and hemoabdomen. The IP-treated dogs had fewer serosal, mesenteric, and omental metastases than historical controls treated with systemic doxorubicin. Results of the postmortem examination and pharmacokinetic analysis confirmed that IP delivery of doxorubicin resulted in an effective drug concentration with a clearance comparable with that after IV delivery.<\/jats:p>\n                  <jats:p>Conclusions and Clinical Importance: IP pegylated liposomal encapsulated doxorubicin administration did not prevent intra-abdominal recurrence of HSA in dogs.<\/jats:p>","DOI":"10.1111\/j.1939-1676.2007.tb01958.x","type":"journal-article","created":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T08:04:32Z","timestamp":1268294672000},"page":"1347-1354","source":"Crossref","is-referenced-by-count":29,"title":["Clinical and Pharmacokinetic Characteristics of Intracavitary Administration of Pegylated Liposomal Encapsulated Doxorubicin in Dogs with Splenic Hemangiosarcoma"],"prefix":"10.1093","volume":"21","author":[{"given":"Karin","family":"Sorenmo","sequence":"first","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"},{"name":"The Mart Lowe Center for Comparative Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Samluk","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Clifford","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Baez","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Poppenga","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Overley","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Skorupski","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Oberthaler","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom Van","family":"Winkle","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Seller","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances","family":"Shofer","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine of the University of Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,11,1]]},"reference":[{"key":"2026020303383501200_b1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2460\/javma.1988.193.06.706","article-title":"Epidemiclogic, clinical, pathologic, and prognostic characteristics of splenic hemangiosarcoma and splenic hematoma in dogs: 217 cases (1985)","volume":"193","author":"Prymak","year":"1988","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303383501200_b2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1939-1676.1989.tb03092.x","article-title":"Splenomegaly in dogs: Predictors of neoplasia and survival after splenectomy","volume":"3","author":"Johnson","year":"1989","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5326\/15473317-34-5-417","article-title":"Prognosis for dogs with stage I and II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991\u20131993)","volume":"34","author":"Wood","year":"1998","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026020303383501200_b4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2460\/javma.1985.186.01.56","article-title":"Canine hemangiosarcoma: Retrospective analysis of 104 cases","volume":"186","author":"Brown","year":"1985","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303383501200_b5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1939-1676.1991.tb00943.x","article-title":"Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma","volume":"5","author":"Hammer","year":"1991","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1939-1676.1993.tb01033.x","article-title":"Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide","volume":"7","author":"Sorenmo","year":"1993","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1939-1676.1996.tb02085.x","article-title":"Surgery and doxorubicin in dogs with hemangiosarcoma","volume":"10","author":"Ogilvie","year":"1996","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1939-1676.2000.tb02247.x","article-title":"Canine hemangiosarcoma treated with standard chemotherapy and minocycline","volume":"14","author":"Sorenmo","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b9","first-page":"209","article-title":"Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma","volume":"18","author":"Sorenmo","year":"2004","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1748-5827.1976.tb06937.x","article-title":"Malignant haemangioendothe-lioma (angiosarcoma) in the dog","volume":"17","author":"Pearson","year":"1976","journal-title":"J Small Anim Pract"},{"key":"2026020303383501200_b11","first-page":"35","author":"Moulton","year":"1978","edition":"2nd ed"},{"key":"2026020303383501200_b12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0021-9975(78)90012-9","article-title":"Hemangiosarcoma in dogs","volume":"88","author":"Oksanen","year":"1978","journal-title":"J Comp Path"},{"key":"2026020303383501200_b13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1939-1676.2000.tb02262.x","article-title":"Treatment of canine hemangiosarcoma: 2000 and beyond","volume":"14","author":"Clifford","year":"2000","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1939-1676.1991.tb00953.x","article-title":"Intracavitary cisplatin chemotherapy experience with six dogs","volume":"5","author":"Moore","year":"1991","journal-title":"J Vet Intern Med"},{"key":"2026020303383501200_b15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1476-5810.2005.00075.x","article-title":"Evaluation of intracavitary mitoxantrone and carboplatin for treatment of carcinomatosis, sarcomatosis and mesothelioma, with or without malignant effusions: A retrospective analysis of 12 cases (1997\u20132002)","volume":"3","author":"Charney","year":"2005","journal-title":"Vet Comp Oncol"},{"key":"2026020303383501200_b16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0378-4274(00)00201-0","article-title":"Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination","volume":"116","author":"Sadzuka","year":"2000","journal-title":"Toxicol Lett"},{"key":"2026020303383501200_b17","first-page":"15","article-title":"Polyethylene glycol coated (pegy-lated) liposomal doxorubicin","volume":"54","author":"Gabizon","year":"1997","journal-title":"Rationale for use in solid tumors Drugs"},{"key":"2026020303383501200_b18","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1997","journal-title":"Cancer Res"},{"key":"2026020303383501200_b19","first-page":"223","article-title":"Editorial: Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet","volume":"7","author":"Gabizon","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2026020303383501200_b20","first-page":"3672","article-title":"Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes","volume":"72","author":"Vaage","year":"1993","journal-title":"Cancer Res"},{"key":"2026020303383501200_b21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s002800050591","article-title":"Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors","volume":"39","author":"Vail","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026020303383501200_b22","first-page":"1567","article-title":"Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model","volume":"4","author":"Vail","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2026020303383501200_b23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1006\/abio.1998.2943","article-title":"Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography","volume":"266","author":"de Bruijn","year":"1999","journal-title":"Anal Biochem"},{"key":"2026020303383501200_b24","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1018907715905","article-title":"Prolongation of the circulation time of doxorubicin encapsulated liposomes containing polyethylene glycol-derivatized phospholipids: Pharmacokinetic studies in rats and dogs","volume":"10","author":"Gabizon","year":"1993","journal-title":"Pharm Res"},{"issue":"Suppl 4","key":"2026020303383501200_b25","first-page":"1","article-title":"Theoretical and experimental bases of intraperitoneal chemotherapy","volume":"12","author":"Dedrick","year":"1985","journal-title":"Semin Oncol"},{"key":"2026020303383501200_b26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2026020303383501200_b27","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"2026020303383501200_b28","first-page":"161","article-title":"Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: Impact of retroperitoneal nodal disease","volume":"18","author":"Barakat","year":"1997","journal-title":"Eur J Gynaecol Oncol"},{"key":"2026020303383501200_b29","first-page":"1916","article-title":"Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans","volume":"41","author":"Speyer","year":"1981","journal-title":"Cancer Res"},{"key":"2026020303383501200_b30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00001703-199901000-00005","article-title":"Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma","volume":"11","author":"Makhija","year":"1999","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2026020303383501200_b31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0959-8049(96)00044-5","article-title":"Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma","volume":"32","author":"Penna","year":"1996","journal-title":"Eur J Cancer"},{"key":"2026020303383501200_b32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0090-9556(25)07922-X","article-title":"Effect of route administration and liposome entrapment on the metabolism and disposition of Adriamycin in the rat","volume":"10","author":"Parker","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"2026020303383501200_b33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0090-9556(25)07833-X","article-title":"Comparison of lymphatic uptake, metabolism, excretion and biodistribution of free and liposome-entrapped [14C]cytosine beta-D-arabinofurano-side following intraperitoneal administration to rats","volume":"10","author":"Parker","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"2026020303383501200_b34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0005-2736(97)00122-3","article-title":"Lymphatic uptake and biodistribution of liposomes after SC injection. II. Influence of liposomal size, lipid composition and lipid dose","volume":"1328","author":"Oussoren","year":"1997","journal-title":"Biochem Biophys Acta"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2007.tb01958.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/21\/6\/1347\/66678798\/j.1939-1676.2007.tb01958.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/21\/6\/1347\/66678798\/j.1939-1676.2007.tb01958.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:38:49Z","timestamp":1770107929000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/21\/6\/1347\/8450424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":34,"aliases":["10.1892\/06-214.1"],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2007.tb01958.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,11]]},"published":{"date-parts":[[2007,11,1]]}}}